Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Stifel Financial Corp

Stifel Financial Corp lessened its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 71.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,025 shares of the company’s stock after selling 62,582 shares during the quarter. Stifel Financial Corp’s holdings in Fulcrum Therapeutics were worth $89,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of FULC. Braidwell LP acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth $3,817,000. Charles Schwab Investment Management Inc. lifted its position in Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after purchasing an additional 393,202 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth approximately $721,000. Bank of New York Mellon Corp purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $1,158,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Fulcrum Therapeutics by 13.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock worth $9,182,000 after acquiring an additional 176,114 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on FULC shares. Leerink Partnrs downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Leerink Partners reissued a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Trading Down 2.3 %

Fulcrum Therapeutics stock opened at $4.68 on Tuesday. The company’s 50-day moving average price is $3.70 and its two-hundred day moving average price is $5.66. Fulcrum Therapeutics, Inc. has a 52 week low of $2.86 and a 52 week high of $13.70. The stock has a market cap of $252.43 million, a price-to-earnings ratio of -15.10 and a beta of 2.14.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.